SCHEMBL5892041

SCHEMBL5892041

NCCNC(=O)CCCC(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
TPSAB1 Q15661 1/20 0.41
SLC6A5 Q9Y345 2/20 0.41
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.39
FAAH O00519 3/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
HDAC3 O15379 2/20 0.38
HDAC4 P56524 2/20 0.38
HDAC1 Q13547 2/20 0.38
HDAC2 Q92769 2/20 0.38
HDAC10 Q969S8 2/20 0.38
HDAC11 Q96DB2 2/20 0.38
HDAC8 Q9BY41 2/20 0.38
HDAC6 Q9UBN7 2/20 0.38
HDAC9 Q9UKV0 2/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
CASP2 P42575 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2195042 0.93 SLC6A5 (0.47) TSHRSLC6A5FAAHHDAC3HDAC1
SCHEMBL2197667 0.93 SLC6A5 (0.47) TSHRSLC6A5FAAHHDAC3HDAC1
SCHEMBL23813807 0.88 ALDH1A1 (0.40) TSHRTPSAB1SLC6A5ALDH1A1CASP2
SCHEMBL14198853 0.88 SLC6A5 (0.49) TSHRTPSAB1SLC6A5FAAHCA1
SCHEMBL11142780 0.86 CA1 (0.47) TSHRTPSAB1SLC6A5FAAHCA1
SCHEMBL20710352 0.86 SLC6A5 (0.51) TSHRSLC6A5ALDH1A1FAAHHDAC3
SCHEMBL10057792 0.86 SLC6A5 (0.51) TSHRSLC6A5ALDH1A1FAAHHDAC3
SCHEMBL12680340 0.84 LMNA (0.52) TSHRSLC6A5MAPTALDH1A1HDAC3
SCHEMBL38654455 0.83 ALDH1A1 (0.42) TSHRTPSAB1SLC6A5ALDH1A1CASP2
Hydrochloric Acid SCHEMBL31354695 0.83 BLM (0.52) TSHRSLC6A5MAPTALDH1A1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067620-B2 Antibacterial agents THERAVANCE, INC. (US) 2006-06-27 US disclosed
US-20050171010-A1 NOVEL ANTIBACTERIAL AGENTS CUMBERLAND PHARMACEUTICALS INC. 2005-08-04 US disclosed
US-6518242-B1 Derivatives of glycopeptide antibacterial agents THERAVANCE, INC. 2003-02-11 US disclosed
EP-1060189-A1 DERIVATIVES OF GLYCOPEPTIDE ANTIBACTERIAL AGENTS Advanced Medicine, Inc. (US) 2000-12-20 EP disclosed
WO-1999042476-A1 NOVEL ANTIBACTERIAL AGENTS ADVANCED MEDICINE, INC. (US) 1999-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171010-A1 NOVEL ANTIBACTERIAL AGENTS ENGASE, GALE, MGAM TSHR 4026/4885TPSAB1 450/4885SLC6A5 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.